Asan Medical Center: Gastrointestinal Stromal Tumors trials

The registry lists 18 Gastrointestinal Stromal Tumors studies with Asan Medical Center as lead sponsor. 4 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 14Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• GIST Oral Paclitaxel(Liporaxel)RecruitingNCT06326346Phase 2
• Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal TumorRecruitingNCT05905887Phase 2
• The Efficacy and Safety of Temozolomide in SDH-deficient GISTRecruitingNCT05661643Phase 2
• 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskRecruitingNCT05385549Phase 2
• Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258CompletedNCT01440959Phase 2Results posted
• Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHTCompletedNCT01151852Phase 3Results posted
• Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit MutationCompletedNCT00278876Phase 2Results posted
• Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.CompletedNCT03944304Phase 2
• PDR001 Plus Imatinib for Metastatic or Unresectable GISTCompletedNCT03609424Phase 1/2
• Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal TumorCompletedNCT03440515Phase 2
• L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal TumorsCompletedNCT03426722Phase 3
• A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous ThromboembolismStatus unknownNCT03139487Phase 2
• Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTsCompletedNCT02889328Phase 2
• A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTsCompletedNCT02712112Phase 2
• Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and SunitinibCompletedNCT02607332Phase 2
• Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal TumorsWithdrawnNCT02268435Phase 1
• Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDIActive, not recruitingNCT01541709Phase 2
• Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PKCompletedNCT00976612